National Center for Research and Development announed a list of projects recommended for co-financing

WPD Pharmaceuticals will receive founding in the amount 22 033066 PLN for the new drug development as a part of the project “New approach to glioblastoma treatment addressing the critical unmet medical need”. 

On the 31th of January 2019 National Center for Research and Development announed a list of projects recommended for co-financing by the European Union, under the Smart Growth Operational Program 2014-2020, Sectoral Programme InnoNeuroPharm, Priority Axis I: Support R&D carried out by enterprises,Measure 1.2 Sectorial programms R&D.

WPD Pharmaceuticals will receive founding in the amount 22 033066 PLN for the new drug development as a part of the project “New approach to glioblastoma treatment addressing the critical unmet medical need”. 

https://www.ncbr.gov.pl/fileadmin/POIR/3_1.2_2018_innoneuropharm/lista_rankingowa_INNONEUROPHARM_2018.pdf